Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Improving Cardiovascular Health through Innovation The Cardiovascular Research Foundation (CRF) strives to improve the quality of life for patients with cardiovascular disease. Investigate CRF investigates early-stage technologies. We consult for new device and drug therapies, develop unique experimental models, and offer a full range of histopathology services and advanced cardiac imaging. … View more
Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
Author(s): Antoni Bayés-Genís , Christian Muñoz-Guijosa , Evelyn Santiago-Vacas , et al Added: 3 years ago
“The time is always right to do what is right.” – Martin Luther King Jr (1929–1968) Heart failure (HF) has increased at a fast pace during the 21st century to become the main cause of morbidity and mortality for patients with cardiovascular disorders in developed nations, leading to increasing healthcare costs and declining quality of life. The expected prevalence of HF was ~25 million in 2011,… View more

Vascular Disease and Surgery

Heart Failure
ESC 2021 Discussion: The EMPEROR-Preserved Trial
Author(s): Stefan Anker , Harriette Van Spall Added: 2 years ago
Late-breaker host, Dr Harriette Van Spall (McMaster University, CA)is joined by Principal Investigator, Prof Stefan Anker (Charite Campus Virchow Clinic, DE) for an in-depth discussion on the latest data from the EMPEROR-Preserved trial presented at ESC Congress 2021. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction evaluated the effects of… View more

Standards & Guidelines

Heart Failure
EMPEROR-Preserved: Empagliflozin, Health Status, & QoL in Patients With HFpEF
Author(s): Javed Butler Added: 2 years ago
In this short interview, Dr Javed Butler (University of Mississippi Medical Center, Jackson, MS, US) discusses the findings of an analysis from the EMPEROR Preserved trial. In EMPEROR-Preserved, empagliflozin treatment was associated with reduction in the risk of the primary endpoint of CV death or HF hospitalization in patients with HFpEF. In this analysis, presented at AHA 2021, the… View more

Heart Failure

Prevention & Chronic Conditions
Management of Refractory Angina Pectoris
Author(s): Kevin Cheng , Paul Sainsbury , Michael Fisher , et al Added: 3 years ago
Refractory angina (RA) is conventionally defined as a chronic condition (≥3 months in duration) characterised by angina in the setting of coronary artery disease (CAD), which cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and where reversible myocardial ischaemia has been clinically established to be the cause of the symptoms.1 In clinical… View more

Heart Failure

Prevention & Chronic Conditions
Ablation as First-line Therapy for Atrial Fibrillation.
Author(s): Jason G Andrade Added: 8 months ago

Electrophysiology & Arrhythmia
Dr Mauro Lencioni
Job title: Consultant Cardiologist & Electrophysiologist
Mauro Lencioni is a cardiologist at the Queen Elizabeth Hospital, Birmingham. His interests are the treatment of cardiac arrhythmias and the effects of arrhythmia symptoms on quality of life. View more
THT 24: The ALT FLOW Early Feasibility Study
Author(s): Firas Zahr Added: 1 month ago
THT 24 - We are joined by Dr Firas Zahr (OHSU Knight Cardiovascular Institute Cardiology Clinic, US) to discuss the findings from the ALT FLOW Early Feasibility study (NCT03523416).The ALT FLOW Early Feasibility study aims to assess the initial clinical safety, functionality and effectiveness of a transcatheter atrial shunt system created by Edwards. 75 patients with symptomatic heart failure… View more

Heart Failure

Intervention
HFA 23: MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring
Author(s): Jasper J Brugts Added: 11 months ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672). MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of… View more

Heart Failure
Author(s): Harry Crijns Added: 3 years ago
Atrial fibrillation (AF) is the most common arrhythmia. It takes the form of a rapid and irregular heartbeat and pulse rate, and predominantly affects the older population. AF is particularly prevalent in patients with cardiac disease. Patients suffering from AF largely fall into two categories: the elderly with cardiovascular (CV) complications or the young with intrinsic electrical disease. An… View more

Electrophysiology & Arrhythmia